Endo Health Solutions (NSDQ:ENDP) managed to boost its profits by 270% during the 2nd quarter, despite declining sales and a $60 million set-aside for lawsuits filed over the pelvic mesh business it acquired along with American Medical Systems for nearly $3 billion in 2011.
Q2
HeartWare takes a hit despite 75% Q2 sales growth
Shares of HeartWare International (NSDQ:HTWR) came under pressure on Wall Street today after the medical device company missed Wall Street’s loss-per-share forecast on lower-than-expected U.S. sales of its implantable heart pump.
DexCom surges to 52-week high on surging Q2 sales
Dexcom Inc. (NSDQ:DXCM) shares surged to a 52-week high today after the medical device company reported a huge sales surge and boosted its outlook for the rest of the year.
San Diego-based DexCom posted losses of $10.1 million, or 14¢ per share, on sales of $35.8 million during the 3 months ended June 30, cutting losses by 31.3% and growing sales by 53.0%.
Insulet hits 52-week high on 1st positive cash flow
Cutera narrows losses but misses expectations in Q2
Orthofix to restate past financials on revenue snafu | Wall Street Beat
Volcano shares spike following rough Q2 report, upgrade from Wall Street
It’s been a roller-coaster ride for Volcano (NSDQ:VOLC) after posting Q2 earnings at the start of the week. The company posted red ink and missed analysts’ per-share estimates by 2 pennies, but Tuesday share prices jumped almost 8% based as 1 Wall Street analyst upgraded Volcano from "hold" to "buy."
Hologic beats its own Q3 earnings guidance, lowers outlook
Volcano gains on Street-beating Q2 earnings
Wright Medical’s Q2 losses grow on merger, sale costs
Second-quarter losses grew for Wright Medical (NSDQ:WMGI) as the medical device company continued to absorb its acquisition of BioMimetic Therapeutics and to deal with the sale of its hip & knee implant business.
Hanger shares plunge on Q2 earnings
Hanger Inc. (NYSE:HGR) missed the mark in the 2nd quarter, posting numbers that came in well below the Street’s expectations, missing analysts average per-share estimates by 7¢.